Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese biopharmaceutical company, has entered into a partnership with a top-tier Indian pharmaceutical company. The collaboration aims to facilitate the regulatory filing, marketing, and distribution of Kangtai Bio’s dual carrier 13-valent pneumonia vaccine in India.
Indian Pharmaceutical Company’s Extensive Reach
The Indian company, with 26 subsidiaries and over 2,000 distribution centers across the country, presents a significant channel for the expansion of Kangtai Bio’s vaccine in the Indian market. This partnership builds on Kangtai Bio’s previous collaborations with local firms in the Philippines, Indonesia, Pakistan, Saudi Arabia, and other countries for its 13-valent and 23-valent pneumonia vaccines.
India’s Commitment to Immunization and Kangtai Bio’s Contribution
India, the world’s most populous country, has incorporated vaccines for 13 common infectious diseases into its national immunization plan, including certain pneumococcal vaccines. Kangtai Bio’s 13-valent pneumonia vaccine is a valuable addition to this initiative, offering protection against a broader range of serotypes compared to existing vaccines.-Fineline Info & Tech
